Managed Care Research in Action

(R3) Research Podium Session – Leveraging Real-World Data to Advance Managed Care Pharmacy Practice

Tuesday, April 1, 2025

3:15 PM – 4:30 PM CST

Location: 310

ACPE UAN:0233-0000-25-015-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Henriette Coetzer, MD

SVP, Chief Medical Officer
Blue Health Intelligence
Chicago, IL
Ruth Wangia Dixon, PhD

Research Scientist
Carelon Research
Wilmington, DE
Sourab Ganna, PharmD

Student
University of Houston
Houston, TX
Stephen Quillen, PharmD, BCACP, CSP, PA-C

Senior Director, Market and Financial Insights
IPD Analytics
Aventura, FL

Moderator(s)

Laura Happe, PharmD, MPH

Associate Professor, Editor-in-Chief
University of Florida, Journal of Managed Care and Specialty Pharmacy

Each year, hundreds of authors submit research abstracts to AMCP’s Annual Meeting. Accepted abstracts are presented as posters in the Expo Hall and published in a special issue of the Journal of Managed Care + Specialty Pharmacy. Four top abstracts are awarded platinum ribbons and presented at the Research Podium Session.

AMCP 2025’s platinum abstracts had a common theme — use of real-world data to advance managed care pharmacy practice. In this Research Podium Session, authors will describe novel ways to leverage and link datasets to provide a deeper understanding of patients and outcomes.

The platinum abstract award presentations are:

• How do GLP-1 side effects affect cost?
• What is the real-world uptake of bevacizumab biosimilars from 2018 to 2023?
• Cost-Effectiveness of Dextromethorphan-Bupropion (Auvelity) among Major Depressive Disorder adult patients
• Evaluating Medicaid brand-over-generic formulary strategies following the AMP cap removal

Learning Objectives:

At the completion of this activity, participants should be able to:

Identify trends in non-GLP-1 pharmacy utilization for individuals treated with GLP-1s.
Describe real-world uptake of bevacizumab biosimilars and utilization of bevacizumab originator among patients with mCRC and NSCLC from 2018 to 2023.
Indicate the cost-effectiveness of Auvelity compared to standard-of-care therapies in adult MDD patients after failure of first-line antidepressant treatments in the U.S. healthcare system
Describe how the AMP cap removal impacted Medicaid brand-over-generic formulary strategies.